Bangladesh’s 1st homegrown COVID-19 vaccine gets clearance for human trials

DHAKA, July 18– Bangladesh’s first homegrown COVID-19 vaccine has obtained clearance for human trial in phase I. The Bangavax vaccine, developed by local pharmaceutical company Globe Biotech, on Sunday received clearance from the Directorate General of Drug Administration under the Ministry of Health and Family Welfare after the relevant authorities…

DHAKA, July 18 (Xinhua) — Bangladesh’s first homegrown COVID-19 vaccine has obtained clearance for human trial in phase I.

The Bangavax vaccine, developed by local pharmaceutical company Globe Biotech, on Sunday received clearance from the Directorate General of Drug Administration under the Ministry of Health and Family Welfare after the relevant authorities reviewed all the documents on all the previous trials.

“We’ve got the approval for phase I clinical trial of Bangavax,” Mohammad Mohiuddin, a senior official at Globe Biotech, told reporters.

He said the trial will be conducted among 60 healthy volunteers at Bangabandhu Sheikh Mujib Medical University hospital in Dhaka.

In November last year, Bangavax, a single-dose COVID-19 vaccine, got ethical clearance from the Bangladesh Medical Research Council for a human trial on up to 64 healthy adult participants.

Globe Biotech applied for approval for a human trial on Nov. 1 last year, saying its vaccine has yielded “good results” in trials on monkeys.

The vaccine can reportedly be stored at a temperature of 4 degrees Celsius for one month and of -20 degrees Celsius for up to six months. Enditem

ANA NEWS WIRE Disclaimer:
The African News Agency (ANA) is a news wire service and therefore subscribes to the highest standards of journalism as it relates to accuracy, fairness and impartiality.
ANA strives to provide accurate, well sourced and reliable information across Text, Images and Video. Where errors do appear, ANA will seek to correct these timeously and transparently.
The ANA platform also contains news and information from third party sources. ANA has sought to procure reliable content from trusted news sources but cannot be held responsible for the accuracy and opinions provided by such sources on the ANA platform or linked sites.
The content provided for on the ANA News Wire platform, both through the ANA news operation and via its third party sources, are for the sole use of authorised subscribers and partners. Unauthorised access to and usage of ANA content will be subject to legal steps. ANA reserves its rights in this regard.
ANA makes every effort to ensure that the website is up and running smoothly at all times, however ANA does not take responsibility for, and will not be held liable for times when the website is temporarily unavailable due to technical issues that are beyond our control.